Revolution Medicines Inc RVMD

$161.20 +1.77 (1.11%)

Valuation

Market cap
34,483,432,000
Revenue TTM
$0
Net income TTM
$-1,131,300,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.44

Trading

Volume
4,741,800
Avg volume
2,417,320
Day's range
$160.22 – $169.51
Shares out
216,292,000
Stochastic %K
7%
Beta
1.44
Analysts
Strong Buy
Price target
$266.60

Price

Company profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s...

Show more

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 481 6801
Website
https://www.revmed.com
Address
700 Saginaw Drive, Redwood City, United States

Latest news

Stocktwits

None_ Nov 21, 7:16 AM
$RVMD https://www.apexonco.com/triple-meeting-revolution-sets-phase-3-benchmark
0 replies
Stonkhausen Nov 20, 11:02 PM
$RVMD unusual pr hype from the likes of nypost and bbc
0 replies
MrSlick27 Nov 20, 6:11 PM
$RVMD 👀 crazy how this dropped and is skating along the daily 200MA. recent attempts to get back to 170 have been rejected. if 167-170 isn't reclaimed, higher likelihood of seeing 150s
0 replies
Alt_Fuel Nov 20, 6:02 PM
$VSTM $ERAS $RVMD KRAS at Triple Meeting: Erasca wants to one-up RevMed ... Erasca highlighted cross-trial numerical advantages in response rates and tolerability versus RevMed’s agent and is accelerating registrational plans (including a Phase 3 in 1L PDAC potentially in 1H 2027, plus lung cancer trials). It also has a complementary pan-KRAS program (ERAS-4001) with preclinical synergy data. Valuation remains far below RevMed’s, fueling takeover speculation. https://endpoints.news/kras-at-triple-meeting-erasca-wants-to-one-up-revmed-while-alterome-tries-a-different-approach/ https://grok.com/c/e1d8e535-fbab-4c44-890a-94ed32795e7f?rid=357fd6b9-5f71-43af-b503-9ad383c6931f
0 replies
Alt_Fuel Nov 20, 5:56 PM
$VSTM $ERAS $RVMD KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach Erasca presented updated Phase 1 data on its pan-RAS molecular glue ERAS-0015 aiming to differentiate from Revolution Medicines (RevMed), while Alterome shared early data on its distinct KRAS-selective pan-mutant (ON/OFF) inhibitor ALTA3263 at the 38th EORTC-NCI-AACR “Triple” Meeting in Barcelona ( approx. November 20, 2026). Erasca (ERAS-0015) – Seeking to one-up RevMed Erasca positioned ERAS-0015 (a pan-RAS molecular glue, similar in mechanism to RevMed’s daraxonrasib/Rasonque) as potentially more potent and better tolerated. Updated U.S. Phase 1 AURORAS-1 monotherapy data at the 32 mg once-daily dose (pharmacologically active range ~16–32 mg) included: LINK - https://grok.com/c/e1d8e535-fbab-4c44-890a-94ed32795e7f?rid=357fd6b9-5f71-43af-b503-9ad383c6931f
1 replies
Floridahurricanehater Nov 20, 4:21 PM
$RVMD https://www.google.com/search?q=ben+sasse+cancer+now%3F&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari&iga=1&utm_campaign=safari_share_1. $IBRX Prayers for Ben. 🙏🏻🙏🏻 Cancer has come back and he is on Chemo and radiation. But still active. RVMD improved life expectancy average to 12 months.
0 replies
SellasGPS24BAT14 Nov 20, 4:08 PM
$SLS $MRNA $RVMD Close money green $15.00+ SLS009 First line data up next. 4 full trading days left till December 2026. ✌️🙏❤️‍🩹
0 replies
EmSol Nov 20, 3:30 PM
$ALNY $ARGX $GILD $REGN $RVMD dude, Veklury is not covid drug, you are confus with rendesevir.. Veklury is HIV blockbuster drug
0 replies